N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide

Identification

Name
N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
Accession Number
DB07801
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 423.5114
Monoisotopic: 423.238273207
Chemical Formula
C22H29N7O2
InChI Key
WOYITRCGMUXUDE-UHFFFAOYSA-N
InChI
InChI=1S/C22H29N7O2/c1-2-3-11-24-22(31)16-8-7-9-17(13-16)29-18(30)10-5-4-6-12-23-20-19-21(26-14-25-19)28-15-27-20/h7-9,13-15H,2-6,10-12H2,1H3,(H,24,31)(H,29,30)(H2,23,25,26,27,28)
IUPAC Name
N-butyl-3-{6-[(9H-purin-6-yl)amino]hexanamido}benzamide
SMILES
CCCCNC(=O)C1=CC=CC(NC(=O)CCCCCNC2=C3N=CNC3=NC=N2)=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAurora kinase ANot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
24893974
PubChem Substance
99444272
ChemSpider
22377201
BindingDB
50251960
ChEMBL
CHEMBL521105
HET
FXG
PDB Entries
3daj

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0148 mg/mLALOGPS
logP2.34ALOGPS
logP2.5ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)9.87ChemAxon
pKa (Strongest Basic)5.08ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.69 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity122.96 m3·mol-1ChemAxon
Polarizability46.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.915
Caco-2 permeable-0.6133
P-glycoprotein substrateSubstrate0.8048
P-glycoprotein inhibitor IInhibitor0.6389
P-glycoprotein inhibitor IINon-inhibitor0.7524
Renal organic cation transporterNon-inhibitor0.6776
CYP450 2C9 substrateNon-substrate0.8218
CYP450 2D6 substrateNon-substrate0.7667
CYP450 3A4 substrateNon-substrate0.5231
CYP450 1A2 substrateInhibitor0.574
CYP450 2C9 inhibitorNon-inhibitor0.5965
CYP450 2D6 inhibitorNon-inhibitor0.8771
CYP450 2C19 inhibitorNon-inhibitor0.6025
CYP450 3A4 inhibitorNon-inhibitor0.6455
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5957
Ames testNon AMES toxic0.7056
CarcinogenicityNon-carcinogens0.887
BiodegradationNot ready biodegradable0.9774
Rat acute toxicity2.6272 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8927
hERG inhibition (predictor II)Inhibitor0.5994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylaminobenzoic acid and derivatives
Alternative Parents
6-alkylaminopurines / Anilides / Benzamides / N-arylamides / Benzoyl derivatives / Secondary alkylarylamines / Aminopyrimidines and derivatives / Imidolactams / Fatty amides / Imidazoles
show 8 more
Substituents
Acylaminobenzoic acid or derivatives / 6-alkylaminopurine / 6-aminopurine / Benzamide / Imidazopyrimidine / Purine / Anilide / Benzoyl / N-arylamide / Aminopyrimidine
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Details
1. Aurora kinase A
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine/tyrosine kinase activity
Specific Function
Mitotic serine/threonine kinases that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role i...
Gene Name
AURKA
Uniprot ID
O14965
Uniprot Name
Aurora kinase A
Molecular Weight
45809.03 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:26 / Updated on December 01, 2017 15:56